Acetylcysteine: The N-acetyl derivative of CYSTEINE. It is used as a mucolytic agent to reduce the viscosity of mucous secretions. It has also been shown to have antiviral effects in patients with HIV due to inhibition of viral stimulation by reactive oxygen intermediates.Expectorants: Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here.Drug Overdose: Accidental or deliberate use of a medication or street drug in excess of normal dosage.Free Radical Scavengers: Substances that influence the course of a chemical reaction by ready combination with free radicals. Among other effects, this combining activity protects pancreatic islets against damage by cytokines and prevents myocardial and pulmonary perfusion injuries.Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.Drug Incompatibility: The quality of not being miscible with another given substance without a chemical change. One drug is not of suitable composition to be combined or mixed with another agent or substance. The incompatibility usually results in an undesirable reaction, including chemical alteration or destruction. (Dorland, 27th ed; Stedman, 25th ed)Contrast Media: Substances used to allow enhanced visualization of tissues.Hepatic Encephalopathy: A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)Carbocysteine: A compound formed when iodoacetic acid reacts with sulfhydryl groups in proteins. It has been used as an anti-infective nasal spray with mucolytic and expectorant action.Poisoning: A condition or physical state produced by the ingestion, injection, inhalation of or exposure to a deleterious agent.Hepatitis, Alcoholic: INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.Iopamidol: A non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiological procedures.Pulmonary Diffusing Capacity: The amount of a gas taken up, by the pulmonary capillary blood from the alveolar gas, per minute per unit of average pressure of the gradient of the gas across the BLOOD-AIR BARRIER.Acute Kidney Injury: Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.Drug-Induced Liver Injury: A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, and chemicals from the environment.Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)Antioxidants: Naturally occurring or synthetic substances that inhibit or retard the oxidation of a substance to which it is added. They counteract the harmful and damaging effects of oxidation in animal tissues.Infusions, Intravenous: The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.Alanine Transaminase: An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2.CreatinineDrug Therapy, Combination: Therapy with two or more separate preparations given for a combined effect.Cross-Over Studies: Studies comparing two or more treatments or interventions in which the subjects or patients, upon completion of the course of one treatment, are switched to another. In the case of two treatments, A and B, half the subjects are randomly allocated to receive these in the order A, B and half to receive them in the order B, A. A criticism of this design is that effects of the first treatment may carry over into the period when the second is given. (Last, A Dictionary of Epidemiology, 2d ed)Coronary Angiography: Radiography of the vascular system of the heart muscle after injection of a contrast medium.Double-Blind Method: A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.Kidney: Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.Prospective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
(1/2675) JunB forms the majority of the AP-1 complex and is a target for redox regulation by receptor tyrosine kinase and G protein-coupled receptor agonists in smooth muscle cells.

To understand the role of redox-sensitive mechanisms in vascular smooth muscle cell (VSMC) growth, we have studied the effect of N-acetylcysteine (NAC), a thiol antioxidant, and diphenyleneiodonium (DPI), a potent NADH/NADPH oxidase inhibitor, on serum-, platelet-derived growth factor BB-, and thrombin-induced ERK2, JNK1, and p38 mitogen-activated protein (MAP) kinase activation; c-Fos, c-Jun, and JunB expression; and DNA synthesis. Both NAC and DPI completely inhibited agonist-induced AP-1 activity and DNA synthesis in VSMC. On the contrary, these compounds had differential effects on agonist-induced ERK2, JNK1, and p38 MAP kinase activation and c-Fos, c-Jun, and JunB expression. NAC inhibited agonist-induced ERK2, JNK1, and p38 MAP kinase activation and c-Fos, c-Jun, and JunB expression except for platelet-derived growth factor BB-induced ERK2 activation. In contrast, DPI only inhibited agonist-induced p38 MAP kinase activation and c-Fos and JunB expression. Antibody supershift assays indicated the presence of c-Fos and JunB in the AP-1 complex formed in response to all three agonists. In addition, cotransfection of VSMC with expression plasmids for c-Fos and members of the Jun family along with the AP-1-dependent reporter gene revealed that AP-1 with c-Fos and JunB composition exhibited a higher transactivating activity than AP-1 with other compositions tested. All three agonists significantly stimulated reactive oxygen species production, and this effect was inhibited by both NAC and DPI. Together, these results strongly suggest a role for redox-sensitive mechanisms in agonist-induced ERK2, JNK1, and p38 MAP kinase activation; c-Fos, c-Jun, and JunB expression; AP-1 activity; and DNA synthesis in VSMC. These results also suggest a role for NADH/NADPH oxidase activity in some subset of early signaling events such as p38 MAP kinase activation and c-Fos and JunB induction, which appear to be important in agonist-induced AP-1 activity and DNA synthesis in VSMC.  (+info)

(2/2675) N,N'-Diacetyl-L-cystine-the disulfide dimer of N-acetylcysteine-is a potent modulator of contact sensitivity/delayed type hypersensitivity reactions in rodents.

Oral N-acetyl-L-cysteine (NAC) is used clinically for treatment of chronic obstructive pulmonary disease. NAC is easily oxidized to its disulfide. We show here that N,N'-diacetyl-L-cystine (DiNAC) is a potent modulator of contact sensitivity (CS)/delayed type hypersensitivity (DTH) reactions in rodents. Oral treatment of BALB/c mice with 0.003 to 30 micromol/kg DiNAC leads to enhancement of a CS reaction to oxazolone; DiNAC is 100 to 1000 times more potent than NAC in this respect, indicating that it does not act as a prodrug of NAC. Structure-activity studies suggest that a stereochemically-defined disulfide element is needed for activity. The DiNAC-induced enhancement of the CS reaction is counteracted by simultaneous NAC-treatment; in contrast, the CS reaction is even more enhanced in animals treated with DiNAC together with the glutathione-depleting agent buthionine sulfoximine. These data suggest that DiNAC acts via redox processes. Immunohistochemically, ear specimens from oxazolone-sensitized and -challenged BALB/c mice treated with DiNAC display increased numbers of CD8(+) cells. DiNAC treatment augments the CS reaction also when fluorescein isothiocyanate is used as a sensitizer in BALB/c mice; this is a purported TH2 type of response. However, when dinitrofluorobenzene is used as a sensitizer, inducing a purported TH1 type of response, DiNAC treatment reduces the reaction. Treatment with DiNAC also reduces a DTH footpad-swelling reaction to methylated BSA. Collectively, these data indicate that DiNAC in vivo acts as a potent and effective immunomodulator that can either enhance or reduce the CS or DTH response depending on the experimental conditions.  (+info)

(3/2675) Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China.

BACKGROUND: Residents of Qidong, People's Republic of China, are at high risk for development of hepatocellular carcinoma, in part due to consumption of foods contaminated with aflatoxins, which require metabolic activation to become carcinogenic. In a randomized, placebo-controlled, double-blind phase IIa chemoprevention trial, we tested oltipraz, an antischistosomal drug that has been shown to be a potent and effective inhibitor of aflatoxin-induced hepatocarcinogenesis in animal models. METHODS: In 1995, 234 adults from Qidong were enrolled. Healthy eligible individuals were randomly assigned to receive by mouth 125 mg oltipraz daily, 500 mg oltipraz weekly, or a placebo. Sequential immunoaffinity chromatography and liquid chromatography coupled to mass spectrometry or to fluorescence detection were used to identify and quantify phase 1 and phase 2 metabolites of aflatoxin B1 in the urine of study participants. Reported P values are two-sided. RESULTS: One month of weekly administration of 500 mg oltipraz led to a 51% decrease in median levels of the phase 1 metabolite aflatoxin M1 excreted in urine compared with administration of a placebo (P = .030), but it had no effect on levels of a phase 2 metabolite, aflatoxin-mercapturic acid (P = .871). By contrast, daily intervention with 125 mg oltipraz led to a 2.6-fold increase in median aflatoxin-mercapturic acid excretion (P = .017) but had no effect on excreted aflatoxin M1 levels (P = .682). CONCLUSIONS: Intermittent, high-dose oltipraz inhibited phase 1 activation of aflatoxins, and sustained low-dose oltipraz increased phase 2 conjugation of aflatoxin, yielding higher levels of aflatoxin-mercapturic acid. While both mechanisms can contribute to protection, this study highlights the feasibility of inducing phase 2 enzymes as a chemopreventive strategy in humans.  (+info)

(4/2675) Proteasome-dependent degradation of the human estrogen receptor.

In eukaryotic cells, the ubiquitin-proteasome pathway is the major mechanism for the targeted degradation of proteins with short half-lives. The covalent attachment of ubiquitin to lysine residues of targeted proteins is a signal for the recognition and rapid degradation by the proteasome, a large multi-subunit protease. In this report, we demonstrate that the human estrogen receptor (ER) protein is rapidly degraded in mammalian cells in an estradiol-dependent manner. The treatment of mammalian cells with the proteasome inhibitor MG132 inhibits activity of the proteasome and blocks ER degradation, suggesting that ER protein is turned over through the ubiquitin-proteasome pathway. In addition, we show that in vitro ER degradation depends on ubiquitin-activating E1 enzyme (UBA) and ubiquitin-conjugating E2 enzymes (UBCs), and the proteasome inhibitors MG132 and lactacystin block ER protein degradation in vitro. Furthermore, the UBA/UBCs and proteasome inhibitors promote the accumulation of higher molecular weight forms of ER. The UBA and UBCs, which promote ER degradation in vitro, have no significant effect on human progesterone receptor and human thyroid hormone receptor beta proteins.  (+info)

(5/2675) Critical role of glass fiber length in TNF-alpha production and transcription factor activation in macrophages.

Recent studies have demonstrated that dielectrophoresis is an efficient method for the separation of fibers according to fiber length. This method allows the investigation of fiber-cell interactions with fiber samples of the same composition but of different lengths. In the present study, we analyzed the effects of length on the interaction between glass fibers and macrophages by focusing on production of the inflammatory cytokine tumor necrosis factor (TNF)-alpha in a mouse macrophage cell line (RAW 264.7). The underlying molecular mechanisms controlling TNF-alpha production were investigated at the gene transcription level. The results show that glass fibers induced TNF-alpha production in macrophages and that this induction was associated with activation of the gene promoter. Activation of the transcription factor nuclear factor (NF)-kappaB was responsible for this induced promoter activity. The inhibition of both TNF-alpha production and NF-kappaB activation by N-acetyl-L-cysteine, an antioxidant, indicates that generation of oxidants may contribute to the induction of this cytokine and activation of this transcription factor by glass fibers. Long fibers (17 micrometer) were significantly more potent than short fibers (7 micrometer) in inducing NF-kappaB activation, the gene promoter activity, and the production of TNF-alpha. This fiber length-dependent difference in the stimulatory potency correlated with the fact that macrophages were able to completely engulf short glass fibers, whereas phagocytosis of long glass fibers was incomplete. These results suggest that fiber length plays a critical role in the potential pathogenicity of glass fibers.  (+info)

(6/2675) Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.

Spinocerebellar ataxia type 3, also known as Machado-Joseph disease (SCA3/MJD), is one of at least eight inherited neurodegenerative diseases caused by expansion of a polyglutamine tract in the disease protein. Here we present two lines of evidence implicating the ubiquitin-proteasome pathway in SCA3/MJD pathogenesis. First, studies of both human disease tissue and in vitro models showed redistribution of the 26S proteasome complex into polyglutamine aggregates. In neurons from SCA3/MJD brain, the proteasome localized to intranuclear inclusions containing the mutant protein, ataxin-3. In transfected cells, the proteasome redistributed into inclusions formed by three expanded polyglutamine proteins: a pathologic ataxin-3 fragment, full-length mutant ataxin-3 and an unrelated GFP-polyglutamine fusion protein. Inclusion formation by the full-length mutant ataxin-3 required nuclear localization of the protein and occurred within specific subnuclear structures recently implicated in the regulation of cell death, promyelocytic leukemia antigen oncogenic domains. In a second set of experiments, inhibitors of the proteasome caused a repeat length-dependent increase in aggregate formation, implying that the proteasome plays a direct role in suppressing polyglutamine aggregation in disease. These results support a central role for protein misfolding in the pathogenesis of SCA3/MJD and suggest that modulating proteasome activity is a potential approach to altering the progression of this and other polyglutamine diseases.  (+info)

(7/2675) N-acetyl-L-cysteine inhibits primary human T cell responses at the dendritic cell level: association with NF-kappaB inhibition.

N-acetyl-L-cysteine (NAC) is an antioxidant molecule endowed with immunomodulatory properties. To investigate the effect of NAC on the induction phase of T cell responses, we analyzed its action on human dendritic cells (DC) derived from adherent PBMC cultured with IL-4 and granulocyte-macrophage CSF. We first found that NAC inhibited the constitutive as well as the LPS-induced activity of the transcription factor NF-kappaB. In parallel, NAC was shown to down-regulate the production of cytokines by DC as well as their surface expression of HLA-DR, CD86 (B7-2), and CD40 molecules both at the basal state and upon LPS activation. NAC also inhibited DC responses induced by CD40 engagement. The inhibitory effects of NAC were not due to nonspecific toxicity as neither the viability of DC nor their mannose receptor-mediated endocytosis were modified by NAC. Finally, we found that the addition of NAC to MLR between naive T cells and allogeneic DC resulted in a profound inhibition of alloreactive responses, which could be attributed to a defect of DC as APC-independent T cell responses were not inhibited by NAC. Altogether, our results suggest that NAC might impair the generation of primary immune responses in humans through its inhibitory action on DC.  (+info)

(8/2675) Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3.

We have analyzed the presentation of human histocompatability leukocyte antigen-A*0201-associated tumor peptide antigen MAGE-3271-279 by melanoma cells. We show that specific cytotoxic T lymphocyte (CTL)-recognizing cells transfected with a minigene encoding the preprocessed fragment MAGE-3271-279 failed to recognize cells expressing the full length MAGE-3 protein. Digestion of synthetic peptides extended at the NH2 or COOH terminus of MAGE-3271-279 with purified human proteasome revealed that the generation of the COOH terminus of the antigenic peptide was impaired. Surprisingly, addition of lactacystin to purified proteasome, though partially inhibitory, resulted in the generation of the antigenic peptide. Furthermore, treatment of melanoma cells expressing the MAGE-3 protein with lactacystin resulted in efficient lysis by MAGE-3271-279-specific CTL. We therefore postulate that the generation of antigenic peptides by the proteasome in cells can be modulated by the selective inhibition of certain of its enzymaticactivities.  (+info)

*  Acetylcysteine
... , also known as N-acetylcysteine (NAC), is a medication that is used for the treatment of paracetamol ( ... They found that acetylcysteine was metabolized to S-nitroso-N-acetylcysteine (SNOAC), which increased blood pressure in the ... Acetylcysteine is used in the treatment of obstructive lung disease as an adjuvant treatment. Acetylcysteine has been ... Acetylcysteine is sold as a dietary supplement commonly claiming antioxidant and liver protecting effects. Acetylcysteine has ...
*  DMOZ - Health: Pharmacy: Drugs and Medications: A: Acetylcysteine
Includes information, links and a forum for discussion of this molecule. ...
*  Influenza treatment
"N-acetylcysteine". Altern Med Rev. 5 (5): 467-71. October 2000. PMID 11056417. Kristin Chambers (2009-05-02). "2 flu cases ... See cellular immunity). High concentrations of N-acetylcysteine have been used to enhance growth of these cells. This method is ... The activity of N-acetylcysteine (NAC) against influenza was first suggested in 1966. In 1997 a randomized clinical trial found ... 2000). "Protective effect of n-acetylcysteine in a model of influenza infection in mice". Int J Immunopathol Pharmacol. 13 (3 ...
*  Acetylcysteinamide
N-Acetylcysteine amide (abbrev. NACA, AD4 and also known as acetylcysteinamide) is a amide derivative of N-acetylcysteine that ... "N-Acetylcysteine amide: A derivative to fulfill the promises of N-Acetylcysteine". Free Radical Research. 47 (5): 357-67. doi: ...
*  Cough medicine
Two examples are acetylcysteine and guaifenesin. Antitussives, or cough suppressants, are substances which suppress the ...
*  Glutathione
"Acetylcysteine Monograph for Professionals - Drugs.com". Zhang J, Zhou X, Wu W, Wang J, Xie H, Wu Z (2017). "Regeneration of ... Additionally, compounds such as N-acetylcysteine (NAC) and alpha lipoic acid (ALA, not to be confused with the unrelated alpha- ...
*  Special Obtain
Acetylcysteine) Short Supply Products (i.e. Mediven Stockings) Made to Measure Hosiery Homeopathics Dressings, bandages & ...
*  Neuroprotection
Berk M, Malhi GS, Gray LJ, Dean OM (2013). "The promise of N-acetylcysteine in neuropsychiatry". Trends Pharmacol. Sci. 34 (3 ... Acetylcysteine: It targets a diverse array of factors germane to the pathophysiology of multiple neuropsychiatric disorders ...
*  ACTA2
Identification of acetylcysteine at the NH2 terminus". J. Biol. Chem. 259 (11): 7224-9. PMID 6725286. Ueyama H, Inazawa J, ...
*  Ototoxicity
Once-daily dosing and co-administration of N-acetylcysteine may protect against aminoglycoside-induced ototoxicity. The anti- ... Tepel M (August 2007). "N-Acetylcysteine in the prevention of ototoxicity". Kidney International. 72 (3): 231-2. doi:10.1038/sj ...
*  Azathioprine
A widely used therapy for idiopathic pulmonary fibrosis was azathioprine in combination with prednisone and N-acetylcysteine. A ... The Idiopathic Pulmonary Fibrosis Clinical Research Network (2012). "Prednisone, Azathioprine, and N-Acetylcysteine for ...
*  Rumack-Matthew nomogram
662 cases with evaluation of oral acetylcysteine treatment". Archives of Internal Medicine. 141 (3): 380-5. doi:10.1001/ ... to prognosticate possible liver toxicity as well as allowing a clinician to decide whether to proceed with N-Acetylcysteine ( ...
*  Idiopathic pulmonary fibrosis
N-Acetylcysteine (NAC) is a precursor to glutathione, an antioxidant. It has been hypothesized that treatment with high doses ... 2005). "High-dose acetylcysteine in idiopathic pulmonary fibrosis". N Engl J Med. 353 (21): 2229-2242. doi:10.1056/NEJMoa042976 ... 2014). "Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis". N Engl J Med. 370 (22): 2093-2102. doi:10.1056/ ... Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. NEnglJMed. 2012 May 24;366:1968-77. Commonly used three- ...
*  Gideon Koren
Chen N, Aleksa K, Woodland C, Rieder M, Koren G (April 2008). "N-Acetylcysteine prevents ifosfamide-induced nephrotoxicity in ... Koren has found a way to prevent severe kidney damage caused by the cancer drug ifosfamide by using the antidote n-acetyl cysteine ...
*  Mitochondrial disease
N-acetyl cysteine reverses many models of mitochondrial dysfunction.. In the case of mood disorders, specifically bipolar ... disorder, it is hypothesized that N-acetyl-cysteine (NAC), acetyl-L-carnitine (ALCAR), S-adenosylmethionine (SAMe), coenzyme ...
*  Corneal ulcer
Treatment includes antibiotics and collagenase inhibitors such as acetylcysteine. Surgery in the form of corneal ...
*  Nitrotyrosine
"The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice". Kidney ... "Beneficial effects of n-acetylcysteine on ischaemic brain injury". British Journal of Pharmacology. 130 (6): 1219-26. doi: ... stress may participate in the pathogenesis of diabetes Research shows that nitrotyrosine levels can be reduced by N-acetyl cysteine ...
*  Fioricet
The specific antidote to acetaminophen overdose is N-acetylcysteine. Acute renal failure and upper gastrointestinal bleeding ...
*  Sepsis
A 2012 Cochrane review concluded that N-acetylcysteine does not reduce mortality in those with SIRS or sepsis and may even be ... Szakmany, T; Hauser, B; Radermacher, P (September 2012). "N-acetylcysteine for sepsis and systemic inflammatory response in ...
*  Amanita phalloides
Silibinin and N-acetylcysteine appear to be the therapies with the most potential benefit. Repeated doses of activated carbon ... N-Acetylcysteine has shown promise in combination with other therapies. Animal studies indicate the amatoxins deplete hepatic ... Montanini S, Sinardi D, Praticò C, Sinardi A, Trimarchi G (1999). "Use of acetylcysteine as the life-saving antidote in Amanita ... Chyka P, Butler A, Holliman B, Herman M (2000). "Utility of acetylcysteine in treating poisonings and adverse drug reactions". ...
*  Thiomer
Costa, F; Sousa, DM; Parreira, P; Lamghari, M; Gomes, P; Martins, MCL (2017). "N-acetylcysteine-functionalized coating avoids ... randomized double-blind study to evaluate the safety and efficacy of chitosan-N-acetylcysteine for the treatment of dry eye ...
*  Alcohol
Ozaras R, Tahan V, Aydin S, Uzun H, Kaya S, Senturk H (2003). "N-acetylcysteine attenuates alcohol-induced oxidative stress in ... Metabolite toxicity is reduced in rats fed N-acetylcysteine and thiamine. Although the mechanism is unclear, a meta-analysis of ...
*  Cannabis use disorder
Acetylcysteine (NAC) decreased cannabis use and craving in a trial. Atomoxetine in a small study showed no significant change ... A 2014 Cochrane Collaboration review found insufficient data to evaluate the effectiveness of gabapentin and acetylcysteine in ...
*  NAPQI
The preferred antidote for NAPQI poisoning (usually secondary to paracetamol poisoning) is N-acetylcysteine. It can be given in ... Oral methionine compared with intravenous N-acetyl cysteine for paracetamol overdose". Emerg Med J. 20 (4): 366-7. doi:10.1136/ ... Most hospitals stock the antidote (acetylcysteine), which replenishes the liver's supply of glutathione, allowing the NAPQI to ... paracetamol poisoning paracetamol glucuronidation cytochrome P450 oxidase glutathione acetylcysteine methionine liver failure ...
*  Chromoendoscopy
N-acetylcysteine and acetic acid are typically used for this purpose. One or two minutes after staining with the dye, the ...
Drug overdose, Information about Drug overdose  Drug overdose, Information about Drug overdose
For example, an acetaminophen overdose can be treated with an oral medication, N-acetylcysteine (Mucomyst),if the level of ...
more infohttp://www.faqs.org/health/topics/90/Drug-overdose.html
Acetylcysteine 20% - Drugs.com  Acetylcysteine 20% - Drugs.com
A list of US medications equivalent to Acetylcysteine 20% is available on the Drugs.com website. ... Acetylcysteine 20% is a medicine available in a number of countries worldwide. ... Ingredient matches for Acetylcysteine 20%. Acetylcysteine. Acetylcysteine is reported as an ingredient of Acetylcysteine 20% in ... Acetylcysteine 20%. Acetylcysteine 20% may be available in the countries listed below. ...
more infohttps://www.drugs.com/international/acetylcysteine-20.html
Prescriber Checkup | ACETYLCYSTEINE  Prescriber Checkup | ACETYLCYSTEINE
Prescribing data from Medicare's prescription drug benefit, known as Part D, was compiled and released by the Centers for Medicare and Medicaid Services, the federal agency that oversees the program. The data for 2015 includes more than 1.4 billion prescriptions written by nearly 1.4 million doctors, nurses and other providers. This database lists about 447,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. More than three-fourths of these prescriptions went to patients 65 and older; the rest were for disabled patients. Methodology ». ...
more infohttp://projects.propublica.org/checkup/drugs/4113?by=desc&page=2&sort=drug_claims
Acetylcysteine - Wikipedia  Acetylcysteine - Wikipedia
Redirected from N-acetylcysteine). Acetylcysteine, also known as N-acetylcysteine (NAC), is a medication that is used for the ... They found that acetylcysteine was metabolized to S-nitroso-N-acetylcysteine (SNOAC), which increased blood pressure in the ... Acetylcysteine is the N-acetyl derivative of the amino acid L-cysteine, and is a precursor in the formation of the antioxidant ... Acetylcysteine has been successfully tried as a treatment for a number of psychiatric disorders.[31][32][33] A systematic ...
more infohttps://en.m.wikipedia.org/wiki/N-acetylcysteine
DailyMed - ACETYLCYSTEINE solution  DailyMed - ACETYLCYSTEINE solution
ACETYLCYSTEINE (UNII: WYQ7N0BPYC) (ACETYLCYSTEINE - UNII:WYQ7N0BPYC) ACETYLCYSTEINE. 200 mg in 1 mL. ... 20% Acetylcysteine Solution, USP (200 mg acetylcysteine per mL).. NDC 54868-5670-0 1 x 30 mL vial. ... Reproduction studies of acetylcysteine with isoproterenol have been performed in rats and of acetylcysteine alone in rabbits at ... Dilution of the acetylcysteine (See Preparation of Acetylcysteine Solution for Oral Administration) minimizes the propensity of ...
more infohttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8fd7b5d8-f6b1-4d0a-9ec6-446c5f89762a
N-Acetylcysteine  N-Acetylcysteine
Acetyl cysteine, N-acetyl-L-cysteine, N-acetylcysteine, Acetylcysteine (product), Acetylcysteine (substance), Acetylcysteine, ... n-acetylcysteine, l cysteine n acetyl, n acetyl l cysteine, acetyl cysteine, n acetylcysteine, acetyl cysteine l n, ... N Acetylcysteine, L-Cysteine, N-acetyl-, Acetylcysteine [eyes], Acetylcysteine [paracet pois], Acetylcysteine [resp], N Acetyl ... Roberts Brand of Acetylcysteine, UPSA Brand of Acetylcysteine, Acetylcysteine Roberts Brand, Acetylcysteine UPSA Brand, ...
more infohttp://www.fpnotebook.com/legacy/ER/Pharm/NActylcystn.htm
acetylcysteine (oral, effervescent) | Cigna  acetylcysteine (oral, effervescent) | Cigna
Acetylcysteine is used to treat acetaminophen overdose and help prevent damage to your liver caused by taking large quantities ... Acetylcysteine is an acetaminophen antidote that helps your body preserve a substance that can help detoxify the liver. ... What is acetylcysteine?. Acetylcysteine is an acetaminophen antidote that helps your body preserve a substance that can help ... What should I discuss with my healthcare provider before taking acetylcysteine?. You should not use acetylcysteine if you are ...
more infohttps://www.cigna.com/individuals-families/health-wellness/hw/medications/acetylcysteine-d00762o1
Acetylcysteine Intravenous Advanced Patient Information - Drugs.com  Acetylcysteine Intravenous Advanced Patient Information - Drugs.com
Detailed drug Information for acetylcysteine Intravenous. Includes common brand names, drug descriptions, warnings, side ... Precautions while using acetylcysteine. Your doctor will check your progress closely while you are receiving acetylcysteine. ... Uses for acetylcysteine. Acetylcysteine injection is used to help prevent or lessen liver damage caused by an overdose of ... Proper use of acetylcysteine. A nurse or other trained health professional will give you acetylcysteine in a hospital. ...
more infohttps://www.drugs.com/cons/acetylcysteine-intravenous.html
Acetylcysteine | Side Effects, Dosage, Uses, and More  Acetylcysteine | Side Effects, Dosage, Uses, and More
Acetylcysteine inhalation solution is a prescription medication used to break up thick mucus that can form in your airways if ... What is acetylcysteine?. Acetylcysteine is a prescription drug. It comes in three forms: inhalation solution, injectable ... Make sure someone is with you when you take acetylcysteine.. Warnings for other groups. For pregnant women: Acetylcysteine is a ... Acetylcysteine inhalation solution is only available as a generic drug.. *Acetylcysteine comes in three forms: inhalation ...
more infohttps://www.healthline.com/health/acetylcysteine-inhalation-solution
Mucocedyl (Acetylcysteine) 3M  Mucocedyl (Acetylcysteine) 3M
R05CB01 - Acetylcysteine*S01XA08 - Acetylcysteine*V03AB23 - Acetylcysteine. Pharmaceutical companies: manufacturers, ...
more infohttp://drugs-about.com/drugs-m/mucocedyl.html
N-Acetyl Cysteine (NAC)  - iHerb.com  N-Acetyl Cysteine (NAC) - iHerb.com
Brands A-Z Doctor's Best N-Acetyl Cysteine (NAC) Categories Supplements Antioxidants N-Acetyl Cysteine (NAC) Categories ... Doctor's Best, N-Acetyl Cysteine (NAC) 1 Results (showing 1 - 1 ) Visit Manufacturer's Website » ...
more infohttps://www.iherb.com/c/doctor-s-best/n-acetyl-cysteine-nac
Acetylcysteine - DocCheck Flexikon  Acetylcysteine - DocCheck Flexikon
Acetylcysteine. Synonyms: N-acetylcysteine, N-acetyl-L-cysteine, NAC Trade names: Acetadote®, Mucomyst®, Cetylev® ... Acetylcysteine has a molar mass of 163,20 g·mol−1. The molecular formula is C5H9NO3S. ... Acetylcysteine is found to have confounding effects in laboratory tests utilising the Trinder test. Creatinine, cholesterol, ... Acetylcysteine has the ability to break down disulfide bonds between strands of glycosaminoglycans, contained in bronchial ...
more infohttps://flexikon.doccheck.com/en/Acetylcysteine
N-Acetylcysteine for Weight Loss | Livestrong.com  N-Acetylcysteine for Weight Loss | Livestrong.com
N-acetylcysteine -- a form of the amino acid cysteine -- has powerful health benefits. It may even support weight loss. But ... N-Acetylcysteine Overview. N-acetylcysteine, or NAC, is used to make glutathione, which is one of the body's most important ... Memorial Sloan Kettering Cancer Center: N-Acetylcysteine * American Family Physician: N-Acetylcysteine: Multiple Clinical ... N-acetylcysteine -- a form of the amino acid cysteine -- has powerful health benefits. It may even support weight loss. But ...
more infohttps://www.livestrong.com/article/324104-n-acetyl-cysteine-for-weight-loss/
Cysteamine or N-acetylcysteine for paracetamol poisoning? | The BMJ  Cysteamine or N-acetylcysteine for paracetamol poisoning? | The BMJ
Cysteamine or N-acetylcysteine for paracetamol poisoning? Br Med J 1978; 1 :856 ... Cysteamine or N-acetylcysteine for paracetamol poisoning?. Br Med J 1978; 1 doi: https://doi.org/10.1136/bmj.1.6116.856-a ( ...
more infohttp://www.bmj.com/content/1/6116/856.2
PatientsLikeMe | Acetylcysteine report for  patients like you  PatientsLikeMe | Acetylcysteine report for patients like you
Find the most comprehensive real-world treatment information on Acetylcysteine at PatientsLikeMe. 15 patients with fibromyalgia ... bipolar I disorder or psoriasis currently take Acetylcysteine. ... See also: N-Acetylcysteine NAC Acetylcysteine is a mucolytic ... What are people saying about Acetylcysteine?. There are 4 topics in our forum about Acetylcysteine. ... Currently taking Acetylcysteine Duration. Patients. This item is relevant to you: 2 - 5 years 1 * 1 ...
more infohttps://www.patientslikeme.com/treatments/show/24687-pulmovent-side-effects-and-efficacy
N-Acetylcysteine NAC: uses & side-effects | PatientsLikeMe  N-Acetylcysteine NAC: uses & side-effects | PatientsLikeMe
Find the most comprehensive real-world treatment information on N-Acetylcysteine NAC at PatientsLikeMe. 264 patients with ... bipolar I disorder or psoriasis currently take N-Acetylcysteine NAC. ... Acetyl-Cysteine Flumil Mucomyst-10 Source Naturals N-Acetylcysteine ACC Long Acetylcysteine EG Sach Metagenics N-Acetylcysteine ... What is N-Acetylcysteine NAC?. Category: Supplements Most popular types: GNC N-Acetyl Cysteine ACC 600 Fluimucil Jarrow ...
more infohttps://www.patientslikeme.com/treatments/show/9484-mucomyst10-side-effects-and-efficacy
N-acetylcysteine, an antioxidant supplement, reduces autism symptoms. - latimes  N-acetylcysteine, an antioxidant supplement, reduces autism symptoms. - latimes
The supplement -- N-acetylcysteine, or NAC -- lowered irritability in the ... The supplement -- N-acetylcysteine, or NAC -- lowered irritability in the children and reduced repetitive behaviors, ... N-acetylcysteine reduced symptoms of autism in children in a small pilot… (BioAdvantex Pharma ) ...
more infohttp://articles.latimes.com/2012/may/30/science/la-sci-sn-antioxidant-autism-20120530
Daily Dosage of N-Acetyl Cysteine | Livestrong.com  Daily Dosage of N-Acetyl Cysteine | Livestrong.com
N-acetylcysteine, or NAC, is the supplement form of the amino acid cysteine, which converts to glutathione, a powerful ... University of Michigan Health System; N-Acetyl Cysteine; December 2009 * Beth Israel Deaconess Medical Center; N-Acetyl ... N-acetylcysteine, or NAC, is the supplement form of the amino acid cysteine, which converts to glutathione, a powerful ...
more infohttps://www.livestrong.com/article/485221-daily-dosage-of-n-acetyl-cysteine/
N-Acetylcysteine for Pediatric Trichotillomania - Tabular View - ClinicalTrials.gov  N-Acetylcysteine for Pediatric Trichotillomania - Tabular View - ClinicalTrials.gov
Experimental: N-acetylcysteine (NAC) Patients randomized to this arm will receive N-Acetylcysteine, at a standard dose titrated ... The goal of this trial is to determine the efficacy of N-Acetylcysteine for pediatric trichotillomania. N-Acetylcysteine is a ... N-Acetylcysteine for Pediatric Trichotillomania. The safety and scientific validity of this study is the responsibility of the ... N-Acetylcysteine for Pediatric Trichotillomania. Official Title ICMJE Double-Blind, Placebo-Controlled Trial of N- ...
more infohttps://clinicaltrials.gov/ct2/show/record/NCT00993265
  • Lesniak W, Bala MM, Dubiel B, Gajewski P. Acetylcysteine for preventing contrast-induced nephropathy. (cochrane.org)
  • Studies of N-acetylcysteine used to prevent contrast-induced nephropathy have had mixed results, with disparities in the dosage and amount of hydration protocols. (clinicaladvisor.com)
  • Meta-analyses have concluded that N-acetylcysteine reduces the incidence of contrast-induced nephropathy and may have a greater renal-protective effect in high-risk patients ( Am J Kidney Dis . (clinicaladvisor.com)
  • In chronic renal insufficiency, N-acetylcysteine has been shown to reduce the incidence of contrast-induced nephropathy and is effective prophylactically in high-risk patients ( N Engl J Med . (clinicaladvisor.com)
  • Acetylcysteine protects patients with moderate chronic renal insufficiency from contrast-induced deterioration in renal function after coronary angiographic procedures, with minimal adverse effects and at a low cost" A clinical trial from 2010, however, found that acetylcysteine is ineffective for the prevention of contrast-induced nephropathy. (wikipedia.org)
  • Despite the conflicting research outcomes, the 2012 Kidney Disease: Improving Global Outcomes Guidelines suggest the use of oral acetylcysteine for the prevention of contrast-induced nephropathy in high-risk individuals, given its potential for benefit, low likelihood of adverse effects, and low cost. (wikipedia.org)
  • Although both IV and oral acetylcysteine are equally effective for this indication, oral administration is poorly tolerated because high oral doses are required due to low oral bioavailability , because of its very unpleasant taste and odour, and because of adverse effects , particularly nausea and vomiting. (wikipedia.org)
  • If the predetoxification plasma level is above the line connecting 150 mcg/mL at 4 hours with 37.5 mcg/mL at 12 hours (possible line), continue with maintenance doses of acetylcysteine. (rxlist.com)
  • This study aimed to determine the effects of acute oral N-acetylcysteine (NAC) supplementation on Yo-Yo intermittent recovery test performance level one (YIRT-L1) following repeated-bouts of damaging intermittent exercise. (wellnessresources.com)
  • Oral acetylcysteine is used for the prevention of radiocontrast-induced nephropathy (a form of acute kidney failure). (wikipedia.org)
  • Acetylcysteine Solution, USP is supplied as a sterile unpreserved solution (not for injection) in vials containing a 10% (100 mg/mL) or 20% (200 mg/mL) solution of acetylcysteine as the sodium salt. (nih.gov)
  • Other drugs may interact with acetylcysteine, including prescription and over-the-counter medicines, vitamins, and herbal products. (cigna.com)
  • The supplement -- N-acetylcysteine, or NAC -- lowered irritability in the children and reduced repetitive behaviors, researchers from the Stanford University School of Medicine reported in the journal Biological Psychiatry. (latimes.com)
  • Acetylcysteine has been used for cyclophosphamide-induced hemorrhagic cystitis, although mesna is generally preferred due to the ability of acetylcysteine to diminish the effectiveness of cyclophosphamide. (wikipedia.org)
  • Acetylcysteine is contraindicated in those patients who are sensitive to it. (nih.gov)
  • In addition, acetylcysteine has inhibited viral stimulation by reactive oxygen intermediates, thereby producing antiviral activity in HIV patients. (fpnotebook.com)
  • We randomly assigned 174 patients to receive prednisolone plus N-acetylcysteine (85 patients) or only prednisolone (89 patients). (nih.gov)
  • Inhaled acetylcysteine has been used for mucolytic ("mucus-dissolving") therapy in addition to other therapies in respiratory conditions with excessive and/or thick mucus production. (wikipedia.org)